1. Home
  2. SNBR vs SPRO Comparison

SNBR vs SPRO Comparison

Compare SNBR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sleep Number Corporation

SNBR

Sleep Number Corporation

N/A

Current Price

$4.59

Market Cap

188.2M

ML Signal

N/A

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

N/A

Current Price

$2.59

Market Cap

124.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SNBR
SPRO
Founded
1987
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
188.2M
124.5M
IPO Year
1998
2017

Fundamental Metrics

Financial Performance
Metric
SNBR
SPRO
Price
$4.59
$2.59
Analyst Decision
Hold
Analyst Count
3
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
683.0K
240.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,682,296,000.00
$47,977,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.49
$0.51
52 Week High
$13.94
$3.09

Technical Indicators

Market Signals
Indicator
SNBR
SPRO
Relative Strength Index (RSI) 24.51 70.29
Support Level $3.73 $2.15
Resistance Level $8.94 $2.70
Average True Range (ATR) 0.67 0.10
MACD -0.26 0.03
Stochastic Oscillator 0.31 97.96

Price Performance

Historical Comparison
SNBR
SPRO

About SNBR Sleep Number Corporation

Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: